Symbiosis opens US sales office citing demand from resurgent biotechs

By Gareth Macdonald

- Last updated on GMT

Symbiosis HQ in the UK
Symbiosis HQ in the UK

Related tags Pharmacology Pharmaceutical drug Firm Us

Symbiosis has opened an office in Boston, Massachusetts citing growing demand for vial filling services for highly potent APIs and large molecule injectable formulations.

The office in Cambridge, Boston is intended to let the Scotland, UK-based contractor win more US customers according to a spokesman, who told us “having a local presence obviously helps with existing clients and new potential ones, which we can service locally​.”

Symbiosis – which is hiring more US commercial staff – predicted that growth of the US biotech sector will increase demand for the production of liquid and lyophilised formulations in injectable dosage forms.

The firm cited the industry interest in orphan drugs and personalized medicines as a key driver, explaining that development of production of medicines for smaller patient populations requires a contractor with flexibility and expertise.

US business

Symbiosis has been building its North American customer base since 2015. The plan has been to focus on early-stage biotech companies in need of smaller scale, specialist manufacturing capabilities.

At the time, Symbiosis CEO Colin MacKay told us that US demand for sterile manufacturing was increasing as a result of renewed biotech investment and the growing number of firms developing injectables.

He also said quality problems at US contractors had reduced capacity and created an opportunity for symbiosis.

Despite its US focus, Symbiosis has no plans to set up US manufacturing capacity according to the spokesman, who told us that projects commissioned at the firm’s new US office will be serviced at its facility in Stirling, Scotland.

Related news

Show more

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Follow us